Rivaroxaban tablets have several indications, including reducing the risk of stroke and systemic embolism in nonvalvular ...

Too many people still miss heart trouble Is your heart healthy? In a 2015 study published in JAMA, eight out of 10 men and ...

As per Future Market Insights’ latest industry analysis, the valuation for the global clot busting drugs market is estimated to be around USD 28.8 Billion in 2022 and is projected to exhibit a CAGR ...

The latest results from the phase 3 FIBRONEER-IPF trial showed consistent benefit of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) whether or not they were receiving background ...

Virginia Tech researchers at the Fralin Biomedical Research Institute at VTC have discovered that microscopic structural ...

A novel thrombectomy system met its safety and efficacy goals and improved functional status and quality of life for patients ...

Many patients with heart dysfunction have pulmonary hypertension, more so if they have enlarged hearts or irregular ...